Ginkgo Bioworks Holdings Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Ginkgo Bioworks Holdings Inc 's ROA in the second quarter of 2026?
Ginkgo Bioworks Holdings Inc recorded a cumulative net loss of $-291 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -25.8%.

However, within the Healthcare sector 401 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3576, from total ROA ranking in the first quarter of 2026 at 4189.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-20.17 %	-20.13 %	-5.35 %	-19.7 %	-24.26 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-291	-304	-313	-340	-315
Return On Assets (TTM)	-25.8 %	-25.6 %	-24.93 %	-26.68 %	-23.42 %
DNA's Total Ranking	# 3576	# 4189	# 3692	# 3655	# 3894
Total Assets (TTM) in million	983	1,033	1,304	1,189	1,231
Seq. Total Assets Change	-4.88 %	-20.76 %	9.64 %	-3.4 %	-4.83 %
Seq. Net Income Change	-	-	-	-	-

DNA's 5 Years Annual ROA >> Back to DNA Management Effectiveness >> Compare DNA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 42
Sector	# 402
Overall	# 3550

Return On Assets Statistics
High	Average	Low
1.33 %	-56.99 %	-178.42 %
(Mar 31 2021)		(Sep 30 2022)

Financial Statements
Ginkgo Bioworks Holdings Inc 's Assets	$ 983 million	DNA's Balance sheet
Ginkgo Bioworks Holdings Inc 's Income	$ -47 million	Quarterly DNA's Income Statement
DNA's Income by Division		See DNA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-18.71 %	-36.71 %	-10.33 %	23.27 %	-
Total Assets in million	1,120	1,377	2,176	2,427	1,969
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-313	-547	-893	-2,106	-1,837
Annual Return On Assets	-27.93 %	-39.71 %	-41.02 %	-86.78 %	-93.28 %

DNA's 5 Years Annual ROA >> Back to DNA Management Effectiveness >> Compare DNA ROA to its Competitors

More Return On Assets Ratios
DNA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
DNA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for DNA's Competitors
Subscribers only: Roa for Ginkgo Bioworks Holdings Inc 's Suppliers
Subscribers only: Return On Assets for DNA's Customers

You may also want to know
DNA's Roi	DNA's Inventory Turnover Ratio	DNA's Growth Rates	DNA's Dividend Comparisons
	DNA's Profitability Ratios	DNA's Asset Turnover Ratio	DNA's Dividend Growth
DNA's Roe	DNA's Valuation Ratios	DNA's Financial Strength Ratios	DNA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T15:05:53+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.